APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

New Drug Modeling Solution

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global New Drug Modeling Solution Market Outlook and Growth Opportunities 2026

Report ID 17444082054 July 2026194 pages

Choose your research edition.

Industry ResearchNew Drug Modeling Solution Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal New Drug Modeling Solution Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal New Drug Modeling Solution Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal New Drug Modeling Solution Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal New Drug Modeling Solution Market Analysis and Forecast 2026-2032175 pages · $4,950 USD

Market perspective

The global New Drug Modeling Solution market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for New Drug Modeling Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for New Drug Modeling Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for New Drug Modeling Solution is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the New Drug Modeling Solution market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the New Drug Modeling Solution market include JSR Corporation(Crown Bioscience), Chemical Computing Group ULC, Nimbus Therapeutics, schrodinger, Inc, Genedata AG, Biognos AB, Compugen Ltd, Dassault Systemes and Acellera, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global New Drug Modeling Solution market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of New Drug Modeling Solution and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents New Drug Modeling Solution revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global New Drug Modeling Solution market.

New Drug Modeling Solution Segment by Company

JSR Corporation(Crown Bioscience)

Chemical Computing Group ULC

Nimbus Therapeutics

schrodinger, Inc

Genedata AG

Biognos AB

Compugen Ltd

Dassault Systemes

Acellera

lnstem(Leadscope)

New Drug Modeling Solution Segment by Type

Database

Software

Others

New Drug Modeling Solution Segment by Application

Drug Discovery and Development

Computational Physiological Medicine

Disease Modeling

Others

New Drug Modeling Solution Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global New Drug Modeling Solution status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the New Drug Modeling Solution key companies, revenue, market share, and recent developments.

3. To split the New Drug Modeling Solution breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions New Drug Modeling Solution market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify New Drug Modeling Solution significant trends, drivers, influence factors in global and regions.

6. To analyze New Drug Modeling Solution competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global New Drug Modeling Solution market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of New Drug Modeling Solution and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of New Drug Modeling Solution.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global New Drug Modeling Solution industry.

Chapter 3: Detailed analysis of New Drug Modeling Solution company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of New Drug Modeling Solution in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of New Drug Modeling Solution in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. New Drug Modeling Solution Industry Trends Table 2. New Drug Modeling Solution Industry Drivers Table 3. New Drug Modeling Solution Industry Opportunities and Challenges Table 4. New Drug Modeling Solution Industry Restraints Table 5. Global New Drug Modeling Solution Revenue by Company (US$ Million) & (2021-2026) Table 6. Global New Drug Modeling Solution Revenue Share by Company (2021-2026) Table 7. Global New Drug Modeling Solution Company Ranking, (2024-2026) & (US$ Million) Table 8. Global New Drug Modeling Solution Key Company Manufacturing Base & Headquarters Table 9. Global New Drug Modeling Solution Company, Product Type & Application Table 10. Global New Drug Modeling Solution Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global New Drug Modeling Solution by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Database Table 15. Significant Companies of Software Table 16. Significant Companies of Others Table 17. Global New Drug Modeling Solution Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global New Drug Modeling Solution Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global New Drug Modeling Solution Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global New Drug Modeling Solution Sales Value Share by Type (2021-2026) Table 21. Global New Drug Modeling Solution Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Drug Discovery and Development Table 23. Significant Companies of Computational Physiological Medicine Table 24. Significant Companies of Disease Modeling Table 25. Significant Companies of Others Table 26. Global New Drug Modeling Solution Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global New Drug Modeling Solution Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global New Drug Modeling Solution Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global New Drug Modeling Solution Sales Value Share by Application (2021-2026) Table 30. Global New Drug Modeling Solution Sales Value Share by Application (2027-2032) Table 31. Global New Drug Modeling Solution Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global New Drug Modeling Solution Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global New Drug Modeling Solution Sales Value Share by Region (2021-2026) Table 34. Global New Drug Modeling Solution Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global New Drug Modeling Solution Sales Value Share by Region (2027-2032) Table 36. Global New Drug Modeling Solution Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global New Drug Modeling Solution Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global New Drug Modeling Solution Sales Value Market Share by Country (2021-2026) Table 39. Global New Drug Modeling Solution Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global New Drug Modeling Solution Sales Value Market Share by Country (2027-2032) Table 41. JSR Corporation(Crown Bioscience) Company Information Table 42. JSR Corporation(Crown Bioscience) Business Overview Table 43. JSR Corporation(Crown Bioscience) New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. JSR Corporation(Crown Bioscience) New Drug Modeling Solution Product Portfolio Table 45. JSR Corporation(Crown Bioscience) Recent Development Table 46. Chemical Computing Group ULC Company Information Table 47. Chemical Computing Group ULC Business Overview Table 48. Chemical Computing Group ULC New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Chemical Computing Group ULC New Drug Modeling Solution Product Portfolio Table 50. Chemical Computing Group ULC Recent Development Table 51. Nimbus Therapeutics Company Information Table 52. Nimbus Therapeutics Business Overview Table 53. Nimbus Therapeutics New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Nimbus Therapeutics New Drug Modeling Solution Product Portfolio Table 55. Nimbus Therapeutics Recent Development Table 56. schrodinger, Inc Company Information Table 57. schrodinger, Inc Business Overview Table 58. schrodinger, Inc New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. schrodinger, Inc New Drug Modeling Solution Product Portfolio Table 60. schrodinger, Inc Recent Development Table 61. Genedata AG Company Information Table 62. Genedata AG Business Overview Table 63. Genedata AG New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Genedata AG New Drug Modeling Solution Product Portfolio Table 65. Genedata AG Recent Development Table 66. Biognos AB Company Information Table 67. Biognos AB Business Overview Table 68. Biognos AB New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Biognos AB New Drug Modeling Solution Product Portfolio Table 70. Biognos AB Recent Development Table 71. Compugen Ltd Company Information Table 72. Compugen Ltd Business Overview Table 73. Compugen Ltd New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Compugen Ltd New Drug Modeling Solution Product Portfolio Table 75. Compugen Ltd Recent Development Table 76. Dassault Systemes Company Information Table 77. Dassault Systemes Business Overview Table 78. Dassault Systemes New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Dassault Systemes New Drug Modeling Solution Product Portfolio Table 80. Dassault Systemes Recent Development Table 81. Acellera Company Information Table 82. Acellera Business Overview Table 83. Acellera New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Acellera New Drug Modeling Solution Product Portfolio Table 85. Acellera Recent Development Table 86. lnstem(Leadscope) Company Information Table 87. lnstem(Leadscope) Business Overview Table 88. lnstem(Leadscope) New Drug Modeling Solution Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. lnstem(Leadscope) New Drug Modeling Solution Product Portfolio Table 90. lnstem(Leadscope) Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. New Drug Modeling Solution Product Image Figure 2. Global New Drug Modeling Solution Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global New Drug Modeling Solution Market Size (2021-2032) & (US$ Million) Figure 4. Global New Drug Modeling Solution Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Database Image Figure 8. Software Image Figure 9. Others Image Figure 10. Global New Drug Modeling Solution Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global New Drug Modeling Solution Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global New Drug Modeling Solution Sales Value Share by Type (2021-2032) Figure 13. Drug Discovery and Development Image Figure 14. Computational Physiological Medicine Image Figure 15. Disease Modeling Image Figure 16. Others Image Figure 17. Global New Drug Modeling Solution Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global New Drug Modeling Solution Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global New Drug Modeling Solution Sales Value Share by Application (2021-2032) Figure 20. Global New Drug Modeling Solution Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global New Drug Modeling Solution Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America New Drug Modeling Solution Sales Value (2021-2032) & (US$ Million) Figure 23. North America New Drug Modeling Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe New Drug Modeling Solution Sales Value (2021-2032) & (US$ Million) Figure 25. Europe New Drug Modeling Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific New Drug Modeling Solution Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific New Drug Modeling Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America New Drug Modeling Solution Sales Value (2021-2032) & (US$ Million) Figure 29. South America New Drug Modeling Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa New Drug Modeling Solution Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa New Drug Modeling Solution Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt New Drug Modeling Solution Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Database
  • Software
  • Others
Applications
  • Drug Discovery and Development
  • Computational Physiological Medicine
  • Disease Modeling
  • Others
Companies covered
  • JSR Corporation(Crown Bioscience)
  • Chemical Computing Group ULC
  • Nimbus Therapeutics
  • schrodinger, Inc
  • Genedata AG
  • Biognos AB
  • Compugen Ltd
  • Dassault Systemes
  • Acellera
  • lnstem(Leadscope)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global New Drug Modeling Solution Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global New Drug Modeling Solution Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 New Drug Modeling Solution Market Dynamics
  1. 2.1 New Drug Modeling Solution Industry Trends
  2. 2.2 New Drug Modeling Solution Industry Drivers
  3. 2.3 New Drug Modeling Solution Industry Opportunities and Challenges
  4. 2.4 New Drug Modeling Solution Industry Restraints
3 New Drug Modeling Solution Market by Company
  1. 3.1 Global New Drug Modeling Solution Company Revenue Ranking in 2025
  2. 3.2 Global New Drug Modeling Solution Revenue by Company (2021-2026)
  3. 3.3 Global New Drug Modeling Solution Company Ranking (2024-2026)
  4. 3.4 Global New Drug Modeling Solution Company Manufacturing Base and Headquarters
  5. 3.5 Global New Drug Modeling Solution Company Product Type and Application
  6. 3.6 Global New Drug Modeling Solution Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global New Drug Modeling Solution Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 New Drug Modeling Solution Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 New Drug Modeling Solution Market by Type
  1. 4.1 New Drug Modeling Solution Type Introduction
  2. 4.1.1 Database
  3. 4.1.2 Software
  4. 4.1.3 Others
  5. 4.2 Global New Drug Modeling Solution Sales Value by Type
  6. 4.2.1 Global New Drug Modeling Solution Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global New Drug Modeling Solution Sales Value by Type (2021-2032)
  8. 4.2.3 Global New Drug Modeling Solution Sales Value Share by Type (2021-2032)
5 New Drug Modeling Solution Market by Application
  1. 5.1 New Drug Modeling Solution Application Introduction
  2. 5.1.1 Drug Discovery and Development
  3. 5.1.2 Computational Physiological Medicine
  4. 5.1.3 Disease Modeling
  5. 5.1.4 Others
  6. 5.2 Global New Drug Modeling Solution Sales Value by Application
  7. 5.2.1 Global New Drug Modeling Solution Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global New Drug Modeling Solution Sales Value by Application (2021-2032)
  9. 5.2.3 Global New Drug Modeling Solution Sales Value Share by Application (2021-2032)
6 New Drug Modeling Solution Regional Value Analysis
  1. 6.1 Global New Drug Modeling Solution Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global New Drug Modeling Solution Sales Value by Region (2021-2032)
  3. 6.2.1 Global New Drug Modeling Solution Sales Value by Region: 2021-2026
  4. 6.2.2 Global New Drug Modeling Solution Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America New Drug Modeling Solution Sales Value (2021-2032)
  7. 6.3.2 North America New Drug Modeling Solution Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe New Drug Modeling Solution Sales Value (2021-2032)
  10. 6.4.2 Europe New Drug Modeling Solution Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific New Drug Modeling Solution Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific New Drug Modeling Solution Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America New Drug Modeling Solution Sales Value (2021-2032)
  16. 6.6.2 South America New Drug Modeling Solution Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa New Drug Modeling Solution Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa New Drug Modeling Solution Sales Value Share by Country, 2025 VS 2032
7 New Drug Modeling Solution Country-level Value Analysis
  1. 7.1 Global New Drug Modeling Solution Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global New Drug Modeling Solution Sales Value by Country (2021-2032)
  3. 7.2.1 Global New Drug Modeling Solution Sales Value by Country (2021-2026)
  4. 7.2.2 Global New Drug Modeling Solution Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt New Drug Modeling Solution Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt New Drug Modeling Solution Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt New Drug Modeling Solution Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 JSR Corporation(Crown Bioscience)
  2. 8.1.1 JSR Corporation(Crown Bioscience) Company Information
  3. 8.1.2 JSR Corporation(Crown Bioscience) Business Overview
  4. 8.1.3 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  5. 8.1.4 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Product Portfolio
  6. 8.1.5 JSR Corporation(Crown Bioscience) Recent Developments
  7. 8.2 Chemical Computing Group ULC
  8. 8.2.1 Chemical Computing Group ULC Company Information
  9. 8.2.2 Chemical Computing Group ULC Business Overview
  10. 8.2.3 Chemical Computing Group ULC New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Chemical Computing Group ULC New Drug Modeling Solution Product Portfolio
  12. 8.2.5 Chemical Computing Group ULC Recent Developments
  13. 8.3 Nimbus Therapeutics
  14. 8.3.1 Nimbus Therapeutics Company Information
  15. 8.3.2 Nimbus Therapeutics Business Overview
  16. 8.3.3 Nimbus Therapeutics New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Nimbus Therapeutics New Drug Modeling Solution Product Portfolio
  18. 8.3.5 Nimbus Therapeutics Recent Developments
  19. 8.4 schrodinger, Inc
  20. 8.4.1 schrodinger, Inc Company Information
  21. 8.4.2 schrodinger, Inc Business Overview
  22. 8.4.3 schrodinger, Inc New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  23. 8.4.4 schrodinger, Inc New Drug Modeling Solution Product Portfolio
  24. 8.4.5 schrodinger, Inc Recent Developments
  25. 8.5 Genedata AG
  26. 8.5.1 Genedata AG Company Information
  27. 8.5.2 Genedata AG Business Overview
  28. 8.5.3 Genedata AG New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genedata AG New Drug Modeling Solution Product Portfolio
  30. 8.5.5 Genedata AG Recent Developments
  31. 8.6 Biognos AB
  32. 8.6.1 Biognos AB Company Information
  33. 8.6.2 Biognos AB Business Overview
  34. 8.6.3 Biognos AB New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biognos AB New Drug Modeling Solution Product Portfolio
  36. 8.6.5 Biognos AB Recent Developments
  37. 8.7 Compugen Ltd
  38. 8.7.1 Compugen Ltd Company Information
  39. 8.7.2 Compugen Ltd Business Overview
  40. 8.7.3 Compugen Ltd New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Compugen Ltd New Drug Modeling Solution Product Portfolio
  42. 8.7.5 Compugen Ltd Recent Developments
  43. 8.8 Dassault Systemes
  44. 8.8.1 Dassault Systemes Company Information
  45. 8.8.2 Dassault Systemes Business Overview
  46. 8.8.3 Dassault Systemes New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Dassault Systemes New Drug Modeling Solution Product Portfolio
  48. 8.8.5 Dassault Systemes Recent Developments
  49. 8.9 Acellera
  50. 8.9.1 Acellera Company Information
  51. 8.9.2 Acellera Business Overview
  52. 8.9.3 Acellera New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Acellera New Drug Modeling Solution Product Portfolio
  54. 8.9.5 Acellera Recent Developments
  55. 8.10 lnstem(Leadscope)
  56. 8.10.1 lnstem(Leadscope) Company Information
  57. 8.10.2 lnstem(Leadscope) Business Overview
  58. 8.10.3 lnstem(Leadscope) New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  59. 8.10.4 lnstem(Leadscope) New Drug Modeling Solution Product Portfolio
  60. 8.10.5 lnstem(Leadscope) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst